MS Drug Trials
On this page you'll find helpful links to information about all the current and up and coming MS trials. Usually these clinical MS trials have many phases from the recruitment of patients,right on through there various trial phases and hopefully to FDA approval. These trials are vital in our quest to find a cure. Along the way there are also many approvals for symptom management drugs coming our way to provide relief for coping with the myriad of MS side effects.
*********************************************************************************
On this page you'll find helpful links to information about all the current and up and coming MS trials. Usually these clinical MS trials have many phases from the recruitment of patients,right on through there various trial phases and hopefully to FDA approval. These trials are vital in our quest to find a cure. Along the way there are also many approvals for symptom management drugs coming our way to provide relief for coping with the myriad of MS side effects.
*********************************************************************************
DrugTrial
Masitinib is an oral medication that works by blocking tyrosine kinase, an enzyme essential for the activity of innate immune cells — such as mast cells, microglia, and macrophages — which are thought to drive neuroinflammation and neurodegeneration in progressive MS.
https://multiplesclerosisnewstoday.com/news-posts/2022/01/05/ab-science-okd-start-masitinib-phase-3-trial-progressive-ms/?utm_source=MS&utm_campaign=7c3e969eed-RSS_EMAIL_CAMPAIGN_US&utm_medium=email&utm_term=0_b5fb7a3dae-7c3e969eed-71310153
Global Phase 3 Trials of Fenebrutinib Enrolling Relapsing and PPMS Patients
Two global Phase 3 clinical trials comparing fenebrutinib, an investigational oral BTK inhibitor by Roche, with Aubagio (teriflunomide) are now enrolling adults with relapsing forms of (MS) the NTL MS Society announced in a press release.
https://multiplesclerosisnewstoday.com/news-posts/2021/05/06/fenebrutinib-roche-phase-3-trials-enrolling-relapsing-primary-progressive-ms/?utm_source=MS&utm_campaign=826f938b74-RSS_EMAIL_CAMPAIGN_US&utm_medium=email&utm_term=0_b5fb7a3dae-826f938b74-71310153
Wise Will Seek FDA Approval for Digital Anxiety Management Therapy
Wise Therapeutics intends to seek U.S. Food and Drug Administration (FDA) approval of an anxiety management therapy for multiple sclerosis (MS), following the positive results of a clinical trial. In addition to conducting a proof-of-concept study in MS, Wise tested its digital technique — called attention bias modification (ABM) treatment — in alcohol use disorder
ChariotMS to Test Mavenclad in SPMS, PPMS Patients With Little Ability to Walk
An upcoming Phase 2 clinical trial, called ChariotMS, will test whether Mavenclad (cladribine) can slow a worsening of hand and arm function in people with progressive forms of MS with very limited walking abilities.“We are finding ways to maintain people’s upper limb function is essential to their quality of life,” Klaus Schmierer, PhD, of Queen Mary University of London and Barts Health NHS Trust, said in a press release.
https://multiplesclerosisnewstoday.com/news-posts/2020/11/19/new-trial-for-people-with-advanced-progressive-ms-starting-soon/??utm_medium=desktop-push-notification&utm_source=Notifications&utm_campaign=OneSignal
NCT00451204. Estriol combined with glatiramer acetate (Copaxone) for women with relapsing-remitting multiple sclerosis: a randomised, placebo-controlled, phase 2 trial (phase 3 trial results pending)
Background
Relapses of multiple sclerosis decrease during pregnancy, when the hormone estriol is increased. Estriol treatment is anti inflammatory and neuroprotective in preclinical studies. In a small single-arm study of people with multiple sclerosis estriol reduced gadolinium-enhancing lesions and was favourably immunomodulatory. We assessed whether estriol treatment reduces multiple sclerosis relapses in women.
Study finds link Microglia, Cognitive Declines
a mechanism in the brain’s immune system is ultimately responsible for much of the cognitive impairment and progressive decline that many individuals with multiple sclerosis experience. One of the culprits appears to be Microglia, the brain’s “first responders.
http://msfocus.org/news-details.aspx?newsID=448
a mechanism in the brain’s immune system is ultimately responsible for much of the cognitive impairment and progressive decline that many individuals with multiple sclerosis experience. One of the culprits appears to be Microglia, the brain’s “first responders.
http://msfocus.org/news-details.aspx?newsID=448
Benefits of Cognitive Rehabilitation to Improve Learning
and Memory in People with MS – Six-Month Follow-up Published
http://www.nationalmssociety.org/About-the-Society/News/Study-Provides-Strong-Evidence-for-Benefits-of-%281%29
and Memory in People with MS – Six-Month Follow-up Published
http://www.nationalmssociety.org/About-the-Society/News/Study-Provides-Strong-Evidence-for-Benefits-of-%281%29